Sfoglia per Autore
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
file con accesso da definire2018 Garassino, M; Crino`, L; Catino, A; Ardizzoni, A; Cortesi, E; Cappuzzo, F; Bordi, P; Calabro', L; Barbieri, F; Santo, A; Altavilla, G; Ambrosio, F; Mini, E; Vasile, E; Morgillo, F; Scoppola, A; Bengala, C; Follador, A; Tedde, N; Giannarelli, D; Lo Russo, G; Vitiello, F.
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge
file con accesso da definire2018 Calabro', L; Morra, A; Cornelissen, R; Aerts, J; Maio, M
New Horizons from Immunotherapy in Malignant Pleural Mesothelioma
file con accesso da definire2018 Calabro', L; Rossi, G; Maio, M
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
2018 Calabro', L; Morra, A; Giannarelli, D; Amato, G; D'Incecco, A; Covre, A; Lewis, A; Rebelatto, Mc; Danielli, R; Altomonte, M; Di Giacomo, Am; Maio, M.
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy
2018 Danielli, R; Cisternino, F; Giannarelli, D; Calabro', L; Camerini, R; Savelli, V; Bova, G; Dragonetti, R; Di Giacomo, Am; Altomonte, M; Maio, M
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
2018 Barlesi, F; Vansteenkiste, J; Spigel, D; Ishii, H; Garassino, M; de Marinis, F; Özgüroğlu, M; Szczesna, A; Polychronis, A; Uslu, R; Krzakowski, M; Lee, J-S; Calabro', L; Frontera, Oa; Ellers-Lenz, B; Bajars, M; Ruisi, M; Park, R.
Immunotherapy of brain metastases: breaking a “dogma”
file con accesso da definire2019 Di Giacomo, Am; Valente, M; Cerase, A; Lofiego, Mf; Piazzini1, F; Calabro', L; Gambale, E; Covre, A; Maio, M
The future of mesothelioma treatment: time to shift gear
2019 Maio, M; Calabro', L
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy
file con accesso da definire2019 Sottile, R; Tannazi, M; Johansson, Mh; Cristiani, Cm; Calabro', L; Ventura, V; Cutaia, O; Chiarucci, C; Covre, A; Garofalo, C; Pontén, V; Tallerico, R; Frumento, P; Micke, P; Maio, M; Kärre1, K; Carbone, E.
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
file con accesso da definire2019 Landi, L; D’Inca', F; Gelibter, A; Chiari, R; Grossi, F; Delmonte, A; Passaro, A; Signorelli, D; Gelsomino, F; Galetta, D; Giannarelli, D; Soto Parra, H; Minuti, G; Tiseo, M; Migliorino, Mr; Cognetti, F; Toschi, L; Bidoli, P; Piantedosi, F; Calabro', L; Cappuzzo, F
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
file con accesso da definire2019 Crino', L; Bidoli, P; Delmonte, A; Grossi, F; DE MARINIS, F; Ardizzoni, A; Vitiello, F; LO RUSSO, G; SOTO PARRA, H; Cortesi, E; Cappuzzo, F; Calabro', L; Tiseo, M; Turci, D; Gamucci, T; Antonelli, P; Morabito, A; Chella, A; Giannarelli, D; Galetta, D
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
2019 Antonia, S; Balmanoukian, A; Brahmer, J; Ou, S-H; Hellmann, M; Kim, S-W; Ahn, M-J; Kim, D-W; Gutierrez, M; Liu, S; Schöffski, P; Jäger, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro', L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, P; Rebelatto, M; Narwal, R; Liang, M; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, Ak; Khleif, Sn; Segal, Nh
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy
2020 Bellone, M; Brevi, A; Bruzzì, S; Consonni, M; De Santis, F; Di Lullo, G; Majorini, Mt; Pasto', A; Amadori, A; Bregni, M; Di Nicola, M; Calabro', L; Ferrucci, Pf; Proietti, E; Colombo, Mp; Russo, V
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
2020 Russo, A; Russano, M; Franchina, T; Migliorino, M; Aprile, G; Mansueto, G; Berruti, A; Falcone, A; Aieta, M; Gelibter, A; Russo, A; Barni, S; Maio, M; Martelli, O; Pantano, F; Iacono, D; Calvetti, L; Quadrini, S; Roca, E; Vasile, E; Imperatori, M; Occhipinti, M; Galvano, A; Petrelli, F; Calabro', L; Pasquini, G; Intagliata, S; Ricciardi, G; Tonini, G; Santini, D.; Adamo, V.
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab
2020 Pantano, F; Russano, M; Berruti, A; Mansueto, G; Migliorino, Mr; Adamo, V; Aprile, G; Gelibter, A; Ficorella, C; Falcone, A; Russo, A; Aieta, M; Maio, M; Martelli, O; Barni, A; Napolitano, A; Roca, E; Quadrini, S; Iacono, D; Russo, A; Calvetti, L; Occhipinti, M; Cortellini, A; Vasile, E; Passiglia, F; Imperatori, M; Calabro', L; Di Giacomo, Am; Petrelli, F; Pasquini, G; Franchina, T; Venditti, O; Intagliata, S; Galvano, A; Fioroni, I; Vincenzi, B; Tonini, G; Santini, D
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
2020 Maio, M; Hamid, O; Larkin, J; Covre, A; Altomonte, M; Calabro', L; Vardhana, Sa; Robert, C; Ibrahim, R; Anichini, A; Wolchok, J; Anna Maria Di, Giacomo
Challenges in lung cancer therapy during the COVID-19 pandemic
2020 Calabro', L; Peters, S; Soria, J-P; Di Giacomo, Am; Barlesi, F; Covre, A; Altomonte, M; Vegni, V; Gridelli, C; Reck, M; Rizvi, N; Maio, M
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
2020 Chiarucci, C; Cannito, S; Daffinà, M G; Amato, G; Giacobini, G; Cutaia, O; Lofiego, Mf; Fazio, C; Giannarelli, D; Danielli, R; Di Giacomo, Am; Coral, S; Calabro', L; Maio, M; Covre, A
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
2021 Calabro', L; Rossi, G; Morra, A; Rosati, C; Cutaia, O; Daffinà, Mg; Altomonte, M; Di Giacomo, Am; Casula, M; Fazio, C; Palmieri, G; Giannarelli, D; Covre, A; Maio, M
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
2021 Ayap, Timothy; Nakagawa, Kazuhiko; Fujimoto, Nobukazu; Kuribayashi, Kozo; Kyrre Guren, Tormod; Calabro', Luana; Shapira-Frommer, Ronnie; Gao, Bo; Kao, Steven; Matos, Ignacio; Planchard, David; Chatterjee, Arkendu; Jin, Fan; Norwood, Kevin; Kindler, Hedy L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program | 2018 | Garassino, M; Crino`, L; Catino, A; Ardizzoni, A; Cortesi, E; Cappuzzo, F; Bordi, P; Calabro', L;... Barbieri, F; Santo, A; Altavilla, G; Ambrosio, F; Mini, E; Vasile, E; Morgillo, F; Scoppola, A; Bengala, C; Follador, A; Tedde, N; Giannarelli, D; Lo Russo, G; Vitiello, F. | file con accesso da definire |
| Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge | 2018 | Calabro', L; Morra, A; Cornelissen, R; Aerts, J; Maio, M | file con accesso da definire |
| New Horizons from Immunotherapy in Malignant Pleural Mesothelioma | 2018 | Calabro', L; Rossi, G; Maio, M | file con accesso da definire |
| Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study | 2018 | Calabro', L; Morra, A; Giannarelli, D; Amato, G; D'Incecco, A; Covre, A; Lewis, A; Rebelatto, Mc;... Danielli, R; Altomonte, M; Di Giacomo, Am; Maio, M. | |
| Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy | 2018 | Danielli, R; Cisternino, F; Giannarelli, D; Calabro', L; Camerini, R; Savelli, V; Bova, G; Dragon...etti, R; Di Giacomo, Am; Altomonte, M; Maio, M | |
| Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study | 2018 | Barlesi, F; Vansteenkiste, J; Spigel, D; Ishii, H; Garassino, M; de Marinis, F; Özgüroğlu, M; Szc...zesna, A; Polychronis, A; Uslu, R; Krzakowski, M; Lee, J-S; Calabro', L; Frontera, Oa; Ellers-Lenz, B; Bajars, M; Ruisi, M; Park, R. | |
| Immunotherapy of brain metastases: breaking a “dogma” | 2019 | Di Giacomo, Am; Valente, M; Cerase, A; Lofiego, Mf; Piazzini1, F; Calabro', L; Gambale, E; Covre,... A; Maio, M | file con accesso da definire |
| The future of mesothelioma treatment: time to shift gear | 2019 | Maio, M; Calabro', L | |
| NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy | 2019 | Sottile, R; Tannazi, M; Johansson, Mh; Cristiani, Cm; Calabro', L; Ventura, V; Cutaia, O; Chiaruc...ci, C; Covre, A; Garofalo, C; Pontén, V; Tallerico, R; Frumento, P; Micke, P; Maio, M; Kärre1, K; Carbone, E. | file con accesso da definire |
| Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer | 2019 | Landi, L; D’Inca', F; Gelibter, A; Chiari, R; Grossi, F; Delmonte, A; Passaro, A; Signorelli, D; ...Gelsomino, F; Galetta, D; Giannarelli, D; Soto Parra, H; Minuti, G; Tiseo, M; Migliorino, Mr; Cognetti, F; Toschi, L; Bidoli, P; Piantedosi, F; Calabro', L; Cappuzzo, F | file con accesso da definire |
| Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population | 2019 | Crino', L; Bidoli, P; Delmonte, A; Grossi, F; DE MARINIS, F; Ardizzoni, A; Vitiello, F; LO RUSSO,... G; SOTO PARRA, H; Cortesi, E; Cappuzzo, F; Calabro', L; Tiseo, M; Turci, D; Gamucci, T; Antonelli, P; Morabito, A; Chella, A; Giannarelli, D; Galetta, D | file con accesso da definire |
| Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC | 2019 | Antonia, S; Balmanoukian, A; Brahmer, J; Ou, S-H; Hellmann, M; Kim, S-W; Ahn, M-J; Kim, D-W; Guti...errez, M; Liu, S; Schöffski, P; Jäger, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro', L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, P; Rebelatto, M; Narwal, R; Liang, M; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, Ak; Khleif, Sn; Segal, Nh | |
| Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy | 2020 | Bellone, M; Brevi, A; Bruzzì, S; Consonni, M; De Santis, F; Di Lullo, G; Majorini, Mt; Pasto', A;... Amadori, A; Bregni, M; Di Nicola, M; Calabro', L; Ferrucci, Pf; Proietti, E; Colombo, Mp; Russo, V | |
| Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study | 2020 | Russo, A; Russano, M; Franchina, T; Migliorino, M; Aprile, G; Mansueto, G; Berruti, A; Falcone, A...; Aieta, M; Gelibter, A; Russo, A; Barni, S; Maio, M; Martelli, O; Pantano, F; Iacono, D; Calvetti, L; Quadrini, S; Roca, E; Vasile, E; Imperatori, M; Occhipinti, M; Galvano, A; Petrelli, F; Calabro', L; Pasquini, G; Intagliata, S; Ricciardi, G; Tonini, G; Santini, D.; Adamo, V. | |
| Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab | 2020 | Pantano, F; Russano, M; Berruti, A; Mansueto, G; Migliorino, Mr; Adamo, V; Aprile, G; Gelibter, A...; Ficorella, C; Falcone, A; Russo, A; Aieta, M; Maio, M; Martelli, O; Barni, A; Napolitano, A; Roca, E; Quadrini, S; Iacono, D; Russo, A; Calvetti, L; Occhipinti, M; Cortellini, A; Vasile, E; Passiglia, F; Imperatori, M; Calabro', L; Di Giacomo, Am; Petrelli, F; Pasquini, G; Franchina, T; Venditti, O; Intagliata, S; Galvano, A; Fioroni, I; Vincenzi, B; Tonini, G; Santini, D | |
| Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era | 2020 | Maio, M; Hamid, O; Larkin, J; Covre, A; Altomonte, M; Calabro', L; Vardhana, Sa; Robert, C; Ibrah...im, R; Anichini, A; Wolchok, J; Anna Maria Di, Giacomo | |
| Challenges in lung cancer therapy during the COVID-19 pandemic | 2020 | Calabro', L; Peters, S; Soria, J-P; Di Giacomo, Am; Barlesi, F; Covre, A; Altomonte, M; Vegni, V;... Gridelli, C; Reck, M; Rizvi, N; Maio, M | |
| Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival | 2020 | Chiarucci, C; Cannito, S; Daffinà, M G; Amato, G; Giacobini, G; Cutaia, O; Lofiego, Mf; Fazio, C;... Giannarelli, D; Danielli, R; Di Giacomo, Am; Coral, S; Calabro', L; Maio, M; Covre, A | |
| Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study | 2021 | Calabro', L; Rossi, G; Morra, A; Rosati, C; Cutaia, O; Daffinà, Mg; Altomonte, M; Di Giacomo, Am;... Casula, M; Fazio, C; Palmieri, G; Giannarelli, D; Covre, A; Maio, M | |
| Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study | 2021 | Ayap, Timothy; Nakagawa, Kazuhiko; Fujimoto, Nobukazu; Kuribayashi, Kozo; Kyrre Guren, Tormod; Ca...labro', Luana; Shapira-Frommer, Ronnie; Gao, Bo; Kao, Steven; Matos, Ignacio; Planchard, David; Chatterjee, Arkendu; Jin, Fan; Norwood, Kevin; Kindler, Hedy L. |
Legenda icone
- file ad accesso aperto
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile